Faced with numerous headwinds, Ørsted will slash its workforce numbers by 2,000 by 2027, eliminating a quarter of its current roles, the world’s largest offshore wind developer said on Thursday. Fresh off its $9.35 billion rights issue to raise funds from existing shareholders, Ørsted announced today it is taking another step in the execution of its strategic priorities by reducing its organization by about 2,000 positions by the end of 2027.?? The company will slash jobs as it will focus more on Europe ...

The third-largest shareholder in Orsted plans to participate in the wind developer’s rights issue https://t.co/R8jGZXlCjD ...

Financial Strategy - Orsted 计划发行 94 亿美元（$9.4 billion）的股票[1] Project Funding - 该融资用于海上风电项目[1]

Core Viewpoint - Modus Therapeutics is conducting a fully secured rights issue to raise SEK 28.3 million for the continued development of its drug candidate sevuparin, aimed at treating chronic kidney disease with anemia [1][2][3]. Group 1: Rights Issue Details - The rights issue will provide SEK 28.3 million before issue costs, subject to approval at an extraordinary general meeting on July 29, 2025 [2][3]. - Major shareholders, including Karolinska Development, have committed SEK 17.7 million, covering 62.7% of the rights issue, with the remaining 37.3% underwritten by external parties [4]. Group 2: Purpose and Impact - The funds from the rights issue will be used to complete the ongoing clinical phase II study of sevuparin and to finance operations through the end of 2026 [3]. - The successful securing of the rights issue is viewed as a strong indicator of Modus Therapeutics' clinical strategy and financial health [5]. Group 3: Company Background - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [6][7]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [8].